After months of collaborative development, Ireland-based Aerogen and China’s CanSinoBIO have announced a development and sales partnership for the inhalation delivery of the novel recombinant coronavirus vaccine Convidecia ™ from CanSinoBIO.

The proprietary Aerogen vibration membrane technology is used to deliver active substances via aerosols. The aerosolized vaccine is delivered directly into the patient's airway via a cup dispenser. This pathway simulates the natural infection pathway of the COVID-19 respiratory virus and can bring additional benefits by generating mucosal immunity. 

The interim results of CanSinoBIO's Phase 3 clinical trials have shown that Convidecia ™ is 95.47% effective in preventing serious diseases 14 days after the single-dose vaccination.

The introduction of the vaccine by inhalation as an aerosol requires a much smaller vaccine volume and therefore offers the possibility of administering the CanSinoBIO vaccine inexpensively to many more patients than would have been possible with an injection.

CanSinoBio is currently preparing an application for market approval in China. Further clinical studies for other countries are in preparation.